{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:50:03Z","timestamp":1792277403677,"version":"4.4.0"},"reference-count":10,"publisher":"Wiley","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Ophthalmology"],"published-print":{"date-parts":[[2017]]},"abstract":"<jats:p><jats:italic>Purpose<\/jats:italic>. To evaluate gel microstent (XEN, Aquesys, Inc) for treatment of primary open angle glaucoma (POAG). <jats:italic>Methods<\/jats:italic>. In this prospective interventional study, 13 eyes with POAG underwent XEN implantation with subconjunctival mitomycin-C. Of those eyes, 3 were pseudophakic and 10 underwent simultaneous phacoemulsification and XEN. Patients had uncontrolled IOP, had intolerance to therapy, or had maximal therapy but undergoing cataract extraction. Follow-up visits included IOP, number of medications, vision, and complications and lasted for 1 year. Complete success was defined as IOP reduction \u226520% from preoperative baseline at 1 year without any glaucoma medications while partial success as IOP reduction of \u226520% at 1 year with medications. <jats:italic>Results<\/jats:italic>. IOP dropped from 16\u2009\u00b1\u20094\u2009mmHg pre-op to 9\u2009\u00b1\u20095, 11\u2009\u00b1\u20096, 12\u2009\u00b1\u20095, 12\u2009\u00b1\u20094, and 12\u2009\u00b1\u20093\u2009mmHg at 1 week, 1, 3, 6, and 12 months (<mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\"><mml:mi>p<\/mml:mi><mml:mo>=<\/mml:mo><mml:mn>0.004<\/mml:mn><\/mml:math>, 0.026, 0.034, 0.01, and 0.01, Wilcoxon Signed Ranks) consecutively. BCVA (LogMAR) was 0.33\u2009\u00b1\u20090.34 and improved to 0.13\u2009\u00b1\u20090.11 at 1 year. Mean number of medications dropped from 1.9\u2009\u00b1\u20091 preoperatively to 0.3\u2009\u00b1\u20090.49 (<mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\"><mml:mi>p<\/mml:mi><mml:mo>=<\/mml:mo><mml:mn>0.003<\/mml:mn><\/mml:math>) at 1 year. 42% of eyes achieved complete success and 66% qualified success. Complications included choroidal detachment in 2 eyes, and implant extrusion in 1 eye, and 2 eyes underwent trabeculectomy. <jats:italic>Conclusion<\/jats:italic>. XEN implant is an effective surgical treatment for POAG, with significant reduction in IOP and glaucoma medications at 1 year follow-up.<\/jats:p>","DOI":"10.1155\/2017\/5457246","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T16:03:20Z","timestamp":1488384200000},"page":"1-5","source":"Crossref","is-referenced-by-count":142,"title":["XEN Glaucoma Implant with Mitomycin C 1-Year Follow-Up: Result and Complications"],"prefix":"10.1155","volume":"2017","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9743-4109","authenticated-orcid":true,"given":"Ahmed","family":"Galal","sequence":"first","affiliation":[{"name":"Alpha Vision Augenzentrum, Bremerhaven, Germany"},{"name":"Research Institute of Ophthalmology, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Bilgic","sequence":"additional","affiliation":[{"name":"Alpha Vision Augenzentrum, Bremerhaven, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Eltanamly","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Cairo University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2828-3992","authenticated-orcid":true,"given":"Amr","family":"Osman","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Cairo University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.013"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.10.024"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2014.01.032"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-16625"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S80490"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.10.026"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00473-6"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/j.oftal.2016.02.006"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.03.031"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/847439"}],"container-title":["Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/joph\/2017\/5457246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/joph\/2017\/5457246.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/joph\/2017\/5457246.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T16:03:20Z","timestamp":1488384200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/joph\/2017\/5457246\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":10,"alternative-id":["5457246","5457246"],"URL":"https:\/\/doi.org\/10.1155\/2017\/5457246","relation":{},"ISSN":["2090-004X","2090-0058"],"issn-type":[{"value":"2090-004X","type":"print"},{"value":"2090-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}